Durvalumab combined with concurrent chemoradiotherapy in patients with limited‐stage small cell lung cancer: A prospective, single‐arm, phase 2 clinical trial

作者
Chunyang Song,Xiaohan Zhao,Shuguang Li,Xuehan Guo,Xueyuan Zhang,Xiaobin Wang,Youmei Li,Ke Yan,苏景伟,Jinrui Xu,Shuchai Zhu,Wenbin Shen
出处
期刊:Cancer [Wiley]
卷期号:132 (6): e70351-e70351 被引量:2
标识
DOI:10.1002/cncr.70351
摘要

BACKGROUND: The current standard treatment for limited-stage small cell lung cancer (LS-SCLC) is concurrent chemoradiotherapy (cCRT) plus consolidation immunotherapy, with or without prophylactic cranial irradiation (PCI). However, it remains unknown whether administering immunotherapy concurrently with chemoradiotherapy confers additional benefit. This clinical trial is designed to investigate the efficacy and safety using durvalumab with chemoradiotherapy for LS-SCLC. METHODS: In this single-arm phase 2 study, patients with LS-SCLC received three (1-4) cycles of etoposide, cisplatin, or carboplatin, and durvalumab every 3 weeks, following by thoracic radiotherapy of 60.0 Gy to the gross tumor volume and 54.0 Gy to the planning target volume in 30 once-daily fractions and chemoimmunotherapy. After cCRT plus durvalumab, patients received durvalumab consolidation therapy every 3 weeks for a minimum of 1 year. PCI was recommended to patients with partial or complete response when chemoradiotherapy completed. Efficacy and adverse events were assessed. RESULTS: Overall, 51 patients were enrolled from March 1, 2021, to April 30, 2024, with a median follow-up of 32.0 months. The 1-, 2-, and 3-year progression-free survival (PFS) rates were 56.9%, 35.9%, and 28.2%, respectively, and the median PFS was 17.0 months. The 1-, 2-, and 3-year overall survival (OS) rates were 88.1%, 68.6%, and 49.6%, respectively, and the median OS was 32.0 months. There were 17 (33.4%) patients with grade 3 or 4 adverse events, 7 of which were immune‑related. CONCLUSIONS: These results suggest that the addition of durvalumab to chemoradiotherapy was well tolerated and showed encouraging efficacy, supporting further investigation in patients with LS-SCLC eligible for radical chemoradiotherapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ljx完成签到 ,获得积分10
刚刚
gaojing完成签到,获得积分10
1秒前
Zengyuan完成签到,获得积分10
1秒前
俺寻思者完成签到,获得积分10
2秒前
2秒前
COIN_77完成签到 ,获得积分10
2秒前
搞搞科研完成签到,获得积分10
3秒前
CipherSage的应助被从容冰凡采纳,获得10
4秒前
小小徐完成签到 ,获得积分10
5秒前
sukiii完成签到,获得积分10
5秒前
精神美丽完成签到,获得积分10
5秒前
二巨头完成签到,获得积分10
6秒前
xiaomi完成签到,获得积分10
6秒前
秒速五厘米完成签到,获得积分0
6秒前
bai完成签到,获得积分10
6秒前
高有福完成签到,获得积分20
6秒前
Researcher完成签到,获得积分10
7秒前
7秒前
11111完成签到,获得积分10
7秒前
NexusExplorer的应助被523采纳,获得10
7秒前
flystone发布了新的文献求助20
8秒前
叶若相怜完成签到,获得积分10
8秒前
wxm完成签到,获得积分10
8秒前
小帅完成签到,获得积分10
8秒前
白枫完成签到 ,获得积分10
9秒前
shinhee完成签到,获得积分10
10秒前
拼搏的似狮完成签到,获得积分10
11秒前
11秒前
Wang完成签到,获得积分10
13秒前
Byla发布了新的文献求助10
13秒前
xiaxia42完成签到 ,获得积分10
13秒前
libiqing77完成签到,获得积分10
14秒前
Mars完成签到,获得积分10
14秒前
HUBU完成签到,获得积分10
16秒前
16秒前
纳兰嫣然完成签到,获得积分10
16秒前
123完成签到,获得积分10
16秒前
缓慢的甜瓜完成签到,获得积分10
16秒前
尼斯卡完成签到,获得积分10
16秒前
生物科研小白完成签到 ,获得积分10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173445
求助须知:如何正确求助?哪些是违规求助? 9565680
关于积分的说明 21781107
捐赠科研通 7767599
什么是DOI,文献DOI怎么找? 3431593
关于科研通互助平台的介绍 2555855
邀请新用户注册赠送积分活动 2476788